GlobeNewswire Inc.··Johnson & JohnsonJ&J's SPRAVATO Shows Durable Depression Relief in Real-World Study
Johnson & Johnson's SPRAVATO demonstrates sustained effectiveness for treatment-resistant depression in 570-patient European study, with benefits persisting 6 months post-treatment.
JNJtreatment-resistant depressionreal-world evidence